Lingyao Biotechnology

Lingyao Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, focused on developing next-generation cell therapies for solid tumors. The company utilizes its proprietary L-CAR and TCR-T platforms to create highly specific and potent immune cell products designed to penetrate the tumor microenvironment. Its lead candidate, LY007, is a CAR-T therapy targeting Claudin 18.2 for the treatment of gastric and pancreatic cancers. Additionally, the company is advancing LY001, a TCR-T therapy targeting NY-ESO-1 for various solid tumors. Lingyao Biotechnology aims to address the limitations of current cell therapies in treating solid malignancies through innovative engineering and clinical development.